Bringing Clinical Trials to Life

Oncology

Like our clients, we are committed to the quest to cure cancer. But cancer is not just a single disease. It takes deep trial knowledge to know how to address its many forms. Learn how Synteract has stayed ahead of the trends…More...

Neuro Degenerative

Neuro degenerative disorders are some of the most confounding and complex to affect people. Our specialized experience in these trials aids you in developing treatments that improve functioning and help the lives of both patients and caregivers…More...

Rare & Orphan Disease

Rare and orphan diseases have unique characteristics, not the least of which is finding the right population for your trials. We know the investigators and study sites that can help to address your recruitment goals, among other challenges…More...

Pediatrics

Pediatric trials run the gamut of indications in drug development, but they all have primary things in common – working with children and their families requires specialized expertise and deep knowledge of regulatory requirements….More...

6/1/2018 - 6/5/2018 : ASCO Annual Meeting 25018 More...

4/19/2018: Synteract, an innovative contract research organization (CRO) providing full-service, Phase I-IV services to biopharma companies bringing new medicines to market, has enhanced its focus. More ...

5/11/2018: Synteract Thought Leaders Present at May Conferences - Our experts are hitting the road this month and are presenting at several clinical research conferences around the world. The conferences include the Clinical Leader Forum on May 9 – 10 and Outsourcing Clinical Trials (OCT) Europe on May 15 – 16. Both events bring together clinical trial professionals from around the world.

Synteract Blog 

5/23/2018: Like our clients, we are committed to the quest to cure cancer. But cancer is not just a single disease. It takes deep trial knowledge to know how to address its many forms. In the past 5 years alone, Synteract has managed 175+ clinical oncology trials, with the greatest percentage of those in complex and challenging areas such as pathway-targeted therapies, chemotherapy, and immunotherapy, as well as cell-based therapies and gene therapies. Learn how Synteract has stayed ahead of the trends. https://lnkd.in/ggM8xHW

Synteract on LinkedIn

5/23/2018: We specialize in #studies for diseases that affect a small portion of the population or that are otherwise “forgott… https://t.co/Rj50oYM09X

Synteract Twitter Feed
x

Contact Synteract

Tell us how to stay in touch with you:

*Required